Cardiac Safety Analysis for a Phase HI Trial of Sunitlnib (SU) or Sorafenib (SO) or Placebo (PLC) in Patients (pts) With Resected Renal Cell Carcinoma (RCC)

摘要

Cardiac dysfunction is a well-known risk of tyrosine kinase inhibitor therapy. The mechanism of action is thought to be myocyte metabolic dysfunction. Sunitinib is the best-characterized tyrosine kinase inhibitor, and most analyses of cardiac dysfunction relating to its use are retrospective. Naomi B. Haas, MD, presented cardiac safety data1 from the phase III Eastern Cooperative Oncology Group (ECOG) 2805/ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) trial of adjuvant sorafenib versus sunitinib for patients with completely resected renal cell carcinoma (RCC).